Clinical Approach to Recurrent Voiding Dysfunction, Dysuria, and Pelvic Pain Persisting for at Least 3 Months

Su Jin Kim¹, Khae Hawn Kim²

¹Department of Urology, College of Medicine, Hallym University, Kangdong Sacred Heart Hospital, Seoul, Korea
²Department of Urology, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea

There are several patients with urination problems and urethral and pelvic discomfort. Usually, these patients’ symptoms are persistent and ambiguous; therefore, it is difficult to find underlying diseases associated with the patient’s symptoms. In addition, there are various conditions such as overactive bladder, cystitis, and interstitial cystitis/bladder pain syndrome (IC/BPS). Sometimes patients with other chronic disorders such as fibromyalgia, inflammatory bowel syndrome, and vulvodynia show urination problems and pelvic pain. Thus, a patient-centered approach is important to find the cause of chronic urination problems and pelvic pain. Moreover, IC/BPS should be considered during the diagnostic process because the clinical characteristics of IC/BPS are diverse. In this narrative review, we suggest an integral approach for the diagnosis and treatment of IC/BPS.

Keywords: Cystitis, Interstitial; Urination disorders; Chronic pain; Therapeutics; Physiopathology

• Conflict of Interest: No potential conflict of interest relevant to this article was reported.
patient reports recurrent pain and abnormal sensations in the pelvis, lower abdomen, flanks, urethra, vagina, and/or clitoris, along with voiding symptoms such as urinary frequency, urinary urgency, and nocturia, clinicians must investigate whether these symptoms have persisted for at least 3 months and whether the patient felt anxiety due to the pain and abnormal sensations. Once patients receive treatment, the symptoms may disappear initially but later reappear. As the disease progresses beyond the initial stage, the disappearance of symptoms is delayed and symptom relief may no longer be observed. Since the exact cause is unknown, patients can eventually experience chronic and severe anxiety and depression. Therefore, we can get hints by listening closely to the patients’ descriptions of discomfort that comes to me is like a well-written essay. For accurate diagnosis and targeted therapy, we advise both clinicians and patients to understand the disease progression from the onset of symptoms to the present as an inevitable process from the perspectives of patients and their clinicians. Then, they should consider various viewpoints and endeavor to understand them. Moreover, from the patient's perspective, there is no concept of “disease progression.” Clinicians should therefore empathize with patients, who perceive the disease to have suddenly appeared at the moment when they experience symptoms. Diagnose IC/BPS, both clinicians and patients should begin with awareness and an investigative mindset. Although some medical staff still consider those diseases very rare and potentially unfamiliar, we assert that they affect a substantial number of patients. We shared my experiences: more than 13 million people are suffering from pain syndrome even in the United States, but quite a few patients have been neglected for years or have been misdiagnosed. The disease may even be mistaken for colon disease, heart disease, or pelvic or lower extremity skeletal disease. It is now necessary to raise awareness of IC and BPS through proactive communication between medical consumers and providers based on accurate information [4-9].

If a patient has been treated for cystitis and urinary tract infection and a urine bacterial culture is negative, IC/BPS should be considered. The disease should also be suspected if the pain is limited to the lower abdomen, flanks, waist, urethra, vagina, clitoris, and/or perineal region; if pain exacerbation and relief are linked to the menstrual cycle; and if the pain is related to certain activities such as sexual intercourse or ejaculation. In particular, the bladder should be suspected as a source of symptoms if the patient has pain in the lower extremities (such as on one side of the buttock and thigh), the pain is intermittently or continuously related to bladder filling, and no orthopedic abnormality exists. In these cases, the disease may have progressed significantly. If the pains described above are intermittent or continuous and accompanied by lower urinary tract symptoms such as urinary frequency, urinary urgency, and stress and urge incontinence, patients should ask themselves why they often go to the bathroom — because of an urge to urinate, sickness, or anxiety about getting sick. While long thought to appear only in women, BPS and IC are also found in men. Unlike in women, in men the pain appears in the testicles, scrotum, anus, and perineum, as well as the lower abdomen, urethra, lumbar spine, and tailbone, regardless of bladder filling. Typically, the prostate is first identified as the causative target, and the condition is sometimes simply diagnosed as benign prostatic hyperplasia and prostatitis. At this point, the bladder should be considered as a causative target [10-15].

**CONSIDERING POINTS FOR THE DIAGNOSIS OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME**

Patients have many options for treatment of IC/BPS. Depending on the patient’s condition and age, various treatments are possible, including lifestyle correction and observational treatment, active exercise therapy involving repeated muscle relaxation and contraction, passive exercise therapy, oral drug therapy, intravesical injection therapy, urethral-vaginal injection therapy, and surgical treatment. Although the disease recurs frequently, and the treatment process is exhausting to patients and medical staff, treatment also help the patients. Therefore, an accurate diagnosis and proper professional treatment can contribute to society by improving patients’ overall quality of life and their routine daily lives. The pains and symptoms previously mentioned are the main diagnostic criteria for this group of diseases, and urinary frequency is also commonly observed at the initial stage. Pelvic pain due to bladder filling is a common symptom, but is not currently essential for diagnosis. Among lower urinary tract symptoms, patients commonly misinterpret urinary urgency as pain or fear of urinating unintentionally, but this is also not a requirement for diagnosis. Again, current bladder-related pain and discomfort are the primary and essential diagnostic requirements [16-25].

Mast cells involved in allergic reactions are distributed throughout the blood vessels, lymph glands, and nerves of the bladder, as well as the bladder smooth muscle and mucosa.
Mast cells activated by the involvement of neurological, immunological, and endocrine factors are thought to play a central role in the progression of IC/BPS in many patients [26].

One-fourth of patients who meet the international diagnostic criteria for IC/BPS show a negative result on a potassium chloride sensitivity test, whereas the test result is positive in most women with radiation cystitis, urinary tract infection, chronic prostatitis, and pelvic pain. Thus, this test shows low sensitivity and specificity in diagnosis and is not helpful for therapeutic decision-making.

In fewer than 30% of patients with symptoms of IC/BPS, bladder ulcers, formerly called Hunner ulcers, are found. Notably, the frequency of detecting ulcers varies depending on the diagnostic method. Bladder ulcers are easily identified in general outpatient-based cystoscopy, but some clinicians say that bladder hydrodistension is an easier method to identify vulnerable ulcers. I tend to agree with the latter point of view and use bladder hydrodistension in practice [27-29].

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has developed diagnostic criteria for BPS. If these criteria are strictly applied, the sensitivity of the diagnosis decreases, while the specificity increases. Of note, 90% of the clinical experts who set the NIDDK diagnostic criteria agree with the diagnosis according to these criteria. However, in practice, 60% of patients clinically diagnosed with IC/BPS were shown to not satisfy the NIDDK diagnostic criteria. Thus, using these criteria probably excludes many patients with symptom clusters that are reasonable for diagnosis. That is, the NIDDK criteria are subject to the weakness of high specificity but low sensitivity. IC/BPS is often accompanied by diabetes, fibromyalgia, irritable bowel syndrome (IBS), chronic fatigue syndrome, or atopic allergic reaction. Currently, researchers at the NIDDK’s Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network are investigating the potential associations between disease groups [30-35]. If a patient has a history of using antipsychotic drugs (e.g., ketamine cystitis shows similar symptoms to those of IC/BPS), it is common for inflammation of the lower and upper urinary tract to be comcomitantly present. Therefore, if inflammation of the lower urinary tract not due to bladder cancer or tuberculous cystitis is identified on endoscopy in female patients, it is reasonable to focus on IC/BPS treatment, although another diagnostic therapeutic approach is appropriate if the clinician is unaware of the patient’s drug history [36-39].

When multiple conservative treatments fail, bladder chemodenervation therapy involving the off-label use of botulinum toxin A can be considered. This approach is possible when obstructive voiding symptoms are accompanied by hypertonic pelvic floor muscle abnormalities, along with pelvic floor muscle hypertonia and obvious muscle tenderness [40-43]. However, it should be used with caution in patients with obstructive voiding difficulty.

Currently, the characteristic histological findings of IC/BPS serve no known diagnostic or prognostic value. Even severe microscopic abnormalities are known not to indicate a poor prognosis. Various opinions exist about the meaning of histopathological detection and findings in IC/BPS patients. Currently, 2 opinions are widely held: (1) these findings exclude other diseases showing symptoms similar to those mentioned above and (2) these findings are meaningful as a way to identify inflammatory diseases with similar symptoms. Hence, it is not reasonable to make a diagnostic, therapeutic, and prognostic plan based only on histological findings.

Currently, IC/BPS is considered a genitourinary and anal pain syndrome. However, vulvodynia, testicular pain, perineal pain, genital pain, and anal pain are well known and described as symptomatic syndromes, but the mechanisms and treatments specific to the causes of each pain are not well known. Below are examples of the disease group of prostatitis, which is common in men. Bacterial prostatitis is a disease entity for which diagnostic, therapeutic, and prognostic plans — including its causes and responses to treatment of the causative organism — are well known. In other words, National Institutes of Health (NIH) category 1 and NIH category 2 are included in this disease group and are not correlated to IC/BPS, unlike NIH category 3 (chronic pelvic pain syndrome [CPPS]/nonbacterial prostatitis). The abovementioned explanation will be clearer when looking at each group of diagnoses of exclusion in the form of a cluster of reported symptoms. Among lower urinary tract symptoms, when pelvic pain accompanies storage symptoms, the most common diseases in the differential diagnosis are bladder outlet obstruction, NIH type prostatitis, BPS, and rarely bacterial cystitis and bladder carcinoma in situ. In medical practice, many patients experience unnecessary prostate and bladder neck surgery due to errors in the differential diagnosis when patients are analyzed based on symptoms [44-47]. Therefore, the importance of the differential diagnosis must not be overlooked.

The relationship with urodynamic studies (UDS) can be examined in 2 representative and common aspects. Cystometry
in IC/BPS patients generally shows normal findings, and the characteristic findings are a decrease in bladder capacity and hypersensitivity. In particular, repeated pain accompanying bladder filling strongly suggests IC. Although the mechanism of low bladder compliance is not well known, it may be confused with urge urinary incontinence (a common disease in which bladder compliance decreases) and uninhibited detrusor contraction (a finding of cystometry in frequency-urgency syndrome and neurogenic bladder) [48]. To summarize, bladder compliance is normal up to the point of bladder filling where pain occurs. The second aspect relates to the diagnostic and therapeutic implications when symptoms include bladder pain, no urinary urgency, and detrusor overactivity found on examination. In this case, IC/BPS is excluded diagnostically, a urinary tract infection may be considered, and accordingly, a tendency may exist to prioritize the administration of antibiotics and anticholinergics and botulinum toxin for treatment. However, clinically meaningless detrusor overactivity can be found on examination in 15% of IC/BPS patients, which is the frequency of involuntary contractions in ambulatory UDS among the general population. Hence, clinicians should be aware that there are no diagnostic or therapeutic implications for the reasons described above.

Glomerulation is not a characteristic endoscopic finding only in IC/BPS patients. Therefore, it has little diagnostic and therapeutic value. It can also appear in patients receiving treatment for radiation cystitis and bladder cancer and chemotherapy, and in patients who have not filled their bladder for a long time such as patients on dialysis or urinary diversion. Glomerulation on cystoscopy is not medically significant, particularly in asymptomatic patients [49].

A potential explanatory theory for the effective mechanism of tricyclic antidepressants (e.g., amitriptyline) as therapeutic agents explains the effects by the following mechanisms rather than the original antidepressant effect of the drug: (1) a positive effect on sleep, (2) a blocking effect of the acetylcholine receptor among autonomic nerve system receptors in the bladder, (3) a blocking effect on the histamine receptor, and (4) a palliative effect on neuropathic pain of the somatosensory system. In particular, it is effective to relieve symptoms in patients with overactive bladder, whereas caution is necessary for patients with obstructive voiding symptoms. Moreover, the drug dose for relieving symptoms in IC/BPS patients is lower than that for major depressive symptoms [50-54].

CONSIDERING POINTS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME

I often ponder how to best make decisions regarding patients’ diagnoses and therapeutic prognoses. Although there have been many trials and studies such as potassium chloride testing, intravesical heparin injection, bladder epithelium biopsy, and UDS, cystoscopy and lower-pressure hydrodistension are most helpful. Generally, surgical methods of IC/BPS and a diagnostic method of anesthetic bladder hydrodistension are frequently used. One of the main purposes is to confirm the presence of a Hunner lesion, and 30%–50% of patients show short-term symptom improvements, whereas 30% of patients paradoxically show short-term symptom exacerbation. In particular, an anesthetic maximum bladder capacity of less than 200 mL can be a sign of poor therapeutic prognosis. If the abovementioned ulcer lesions are observed in patients, an excellent therapeutic effect can often be achieved by performing resection, fulguration, or steroid injection on lesion. However, no therapeutic effects have been proven for treatments suggested by some researchers such as reduction cystoplasty, sympathectomy and intraspinal alcohol injection, cystolysis, and transvesical infiltration of the pelvic plexuses with phenol [55-60].

Although several treatments including bacillus Calmette–Guérin 4% lidocaine, botulinum toxin, and heparin were tried, no treatment has been proven effective in double-blind placebo-controlled trials to date. Pentosan polysulfate sodium (PPS), a typical oral medication, is an oral analogue of heparin and targets the restoration of glycosaminoglycan (GAG) of urothe-

Fig. 1. Smart eating out for a healthy bladder.
lium. The currently suggested mechanism is to correct dysfunction of the GAG layer and particularly focuses on the correction of permeability abnormalities. In certain patient groups, caution is necessary since it is associated with visual impairment due to pigmentary maculopathy as a result of long-term administration [61,62].

Opioids, unlike other analgesics, do not have a dose limit for their analgesic effects. Opioids can be useful for IC/BPS patients, although attention should be paid to the fact that opioids can cause physical dependence due to chronic use as the dose is increased to the extent that a patient can endure the side effects of narcotic analgesics and it is necessary to comply with common medical precautions when using opioids.

Although diet control (Figs. 1, 2), physical therapy, and oral administration of PPS can be considered as the primary initial treatment of IC/BPS, the importance of disease awareness and education should be emphasized above all. In particular, patients should understand that even if they follow a reasonable treatment plan, symptom relief can be experienced as chronic progression and repeated improvement and exacerbation of symptoms. This initial education can prevent wasteful doctor shopping, increases in medical costs due to repetitive and excessive examinations, and desperation or extreme damage due to a lack of understanding of the disease. Patients can make the best therapeutic choice in a long-term treatment process focusing on symptoms [63-65].

Below, I present some opinions about situations when invasive surgery is performed due to severely progressed IC/BPS. When a patient has severe symptoms and an accompanying Hunner lesion, anesthetic bladder hydrodistension and Hunner

---

**Fig. 2.** A smart healthy diet for the bladder.
lesion resection are planned and performed. Although bladder hydrodistension is not commonly chosen when the anesthetic maximum bladder capacity is less than 100 mL, I, as an urologist performing surgery, would like to emphasize that clinicians should be aware of unusual prognostic issues when making surgical decisions. In particular, if urethral pain exists among IC/BPS symptoms, it should be kept in mind that clean intermittent catheterization should be maintained in over 30% of patients after bladder hydrodistension. Since Hunner lesions always exist in the supratrigonal area of the trigone, trigonal sparing and supratrigonal cystectomy with bladder augmentation should be considered primarily as surgical methods.

Regarding the risk factors for IC/BPS, the Boston Area Community Health Survey and several community studies of similar size have mentioned emotional, sexual, and physical abuse. In a study conducted in Michigan (control group, n = 464; patient group, n = 215), a difference in exposure to the abovementioned risk factors was observed between the control group (22%) and the patient group (37%). A particularly interesting point was that sexual abuse as a risk factor was associated with fewer cases of exacerbated voiding symptoms, but a remarkable increase in the exacerbation of painful symptoms. Although various opinions exist on the reliability of these 2 studies, it is not reasonable to subdivide the changes in symptoms caused by exposure to risk factors in the medical field. In other words, the possibility of each patient’s sensitivity and specificity to exposure to each risk factor should be considered, and clinicians should be aware of the necessity of collaboration with other departments when the differential diagnosis includes various possible diseases. It should not be recognized as a behavioral pattern associated with IC/BPS, and side effects of treatment or association with patients’ complaints particularly should not be denied.

Hunner lesions could reasonably be recognized as a distinct phenotype distinguished clearly as a separate patient group with unique therapeutic and prognostic specificity, rather than as a comorbid condition in BPS patients. Hunner lesions can be identified by endoscopic and histological examinations, and their frequency increases in elderly patients. As a point of therapeutic significance, the clinical effects of resection, fulguration, and steroid injection have been proven.

Intravesical injection therapy, as a secondary treatment, has a therapeutic effect on bladder pain, especially in bladder-centric pain, and has some effect on fibromyalgia, Hunner lesions, neuropathic pain, and small-capacity bladder. However, no special effect has been observed on vulvodynia accompanying high-tone pelvic floor dysfunction, and caution is necessary since the therapy can worsen the abovementioned symptoms.

**SUMMARY**

The clinical diagnosis of IC/BPS is based on pain, pressure, and discomfort associated with the bladder accompanying lower urinary tract symptoms that persists 6 weeks or more without inflammation or other identified causes. It is generally linked to bladder filling and can be defined as a disease entity for which a diagnosis of exclusion must be conducted using specific tests and markers for other diseases. The frequency of this condition is rapidly increasing as the diagnostic criteria take the form of a clinical symptom complex. Epidemiologically, 3 million women and 2 million men in the United States are known to experience IC/BPS symptoms. In the clinical field, the number of female patients is higher, with a ratio of 5 to 1. Although the accompanying sexual dysfunction in female patients has a clear negative impact on physical and emotional quality of life, diagnosis and treatment are often overlooked.

Commonly co-occurring urogenital functional diseases include overactive bladder syndrome, high-tone pelvic floor dysfunction, and vulvodynia. Other typical functional diseases are fibromyalgia, IBS, chronic fatigue syndrome, atopic allergy, and some rheumatic diseases. Thus, a multidisciplinary collaborative treatment approach among experts from multiple departments and sub-specialties is necessary.

A noteworthy point is that high-tone pelvic floor dysfunction is concomitantly present in 70%–94% of IC/BPS cases and can be identified by voiding dysfunction in UDS or pelvic pain recurring when the pelvic floor muscles are stimulated on a physical examination of the pelvic floor area.

The MAPP research network presents 2 patient groups with distinctive pain phenotypes in IC/BPS: (1) patients who complain only of pelvic pain and (2) patients who report pain in a broader area, as well as pelvic pain. Over 75% of patients are included in the second group, and this statistical distribution can furnish epidemiological evidence supporting the theory that complex pain originates from the central nervous system in the form of neuropathic pain with central sensitization mechanisms.

Hunner lesions, formerly called Hunner ulcers, are a pathognomonic finding of classical IC, which accounts for a minority of IC/BPS patients. It can be easily identified on cystoscopy, and several additional imaging modalities, such as filling the blad-
nder beyond the functional bladder capacity or fluorescent endoscopy, have been used for easier identification. However, subsequent studies have suggested that BPS is a clinical syndrome in the form of a symptom complex and distinct from the minor specific patient groups with Hunner lesions. In addition, in IC/BPS patients who have been diagnosed with a clinical syndrome from a symptomatic perspective, no significant difference exists according to the presence or absence of Hunner lesions and manifestation of clinical symptoms. The progression of the disease involves repeated cycles of waxing and waning and remission and recurrence, and patients undergo a chronic prognostic process. In this process, many patients may experience abrupt and severe exacerbation of symptoms (or flare-ups) for several days. Common risk factors include certain foods, excessive physical activity, sexual contact, and exercise.

In some patients, the diagnostic definition of IC/BPS is sometimes consistent with chronic prostatitis/CPPS, which is NIH category III frequently occurring in men.

In the initial interview with patients, since the preemptive occurrence of prodromal symptoms associated with pelvic pain and irritative symptoms frequently occurs for several to 10 years due to the characteristics of the disease, clinicians should note the presence or absence of prodromal symptoms. The average age of onset of the disease is 40 years old, and onset of symptoms in pediatric patients is very rare. Regarding the epidemiological characteristics specified of family history, the incidence is about 17 times higher in parents, siblings, and children of affected adult women than in the general population.

Ketamine abuse is not a major medical issue in South Korea, but it is an issue associated with IC/BPS in some countries. Although ketamine abuse can occur in all age groups, clinicians should be particularly cautious in the diagnosis when younger patients show the symptomatic combination of IC/BPS regardless of bladder inflammation.

Currently, there is no histological definition of IC/BPS with diagnostic specificity. Although 24%–76% of patients show inflammatory histopathology, most appear to be chronic inflammatory changes without specificity. Hunner lesions can be specified as dense deposits of lymphoplasmacytes on the bladder epithelium throughout the specimen. The significance of a histological examination using cystoscopy is to exclude malignant diseases such as carcinoma in situ and other specific pathological diagnoses. Although recent studies have suggested various perspectives on the causes of IC/BPS symptoms, they can be summarized into 2 perspectives involving minor pathologi-cal processes and major pathological processes, respectively: (1) a local pathological process centered on local and target organs that considers neurogenic inflammation as a cause leading to activation of abnormal mast cells due to leakage of the GAG layer of the bladder epithelium in a small group of patients; and (2) a broad pathological process due to cross-sensitization of organs in the pelvis when the symptoms can be explained by comorbid widespread pain syndrome or complex regional pain syndrome, and immune-mediated pain in a larger group of patients. Pain, pressure sense, and discomfort occur according to the decrease in bladder capacity and bladder filling in IC patients, but bladder compliance is known to be normal on cystometry. Failure to diagnose or overlook causes of pelvic pain that can be overlooked regardless of IC/BPS, such as high-tone pelvic floor dysfunction and vulvodynia, which can be considered a gynecological disease, are the major causes of inadequate treatment of pelvic pain symptoms. Microscopic hematuria and pyuria are not significant predictive factors for Hunner lesions. Therefore, if a Hunner lesion is suspected or there is no response to primary empirical symptom treatment, clinicians should not hesitate to perform an endoscopic examination.

Although bladder hydrodistension is not included in the standard diagnostic process, recent studies have classified anesthetic low bladder capacity appearing in anesthetic bladder hydrodistension as a phenotype with a separate clinical progression. The studies also suggest that anesthetic low bladder capacity tends to appear in patients with more severe symptoms, a low frequency of comorbid diseases such as depression, and IBS beyond the urogenital area, and symptoms that mainly target the bladder. Moreover, since glomerulation (punctiform subepithelial or submucosal hemorrhages) appearing in bladder hydrodistension has low sensitivity and specificity, it is not necessary for the diagnosis.

Treatment for early-stage disease is usually conservative. Prior to treatment, patients should be educated on the disease and specificity of the treatment process. After that, treatment involves dietary control by understanding and sequentially avoiding certain foods and beverages that have negative effects on symptom control, use of versatile nonprescription analgesics, and relaxation training of pelvic floor muscles through physiotherapy. Conservative drug treatment complies with a method of sequentially controlling intensity according to symptom control. At the discretion of medical staff, intensive treatment can alternatively be considered when a patient shows severe symptoms in the initial stage. The symptoms may be further aggra-
vated by increased sensitivity to pain due to patients’ irrational and catastrophic thinking and obsession with or fear of miserable results. This can be controlled sufficiently with cognitive behavioral therapy. Currently, the U.S. Food and Drug Administration (FDA) has approved only 2 medications to treat IC/BPS symptoms: PPS as an oral drug and dimethyl sulfoxide as an intravesical injection drug. Amitriptyline, a tricyclic antidepressant, is not approved by the FDA, but is a major oral drug due to its antihistamine properties, ability to promote sleep, and its effect on relieving central and peripheral neuropathic pain. Although intravesical injection drugs are positively helpful for symptom control, they are limited for pain control according to the increased sensitivity in the nervous system due to the nature of local therapy on the target organs. In addition, no studies have confirmed the effects of the frequency of drug injection, drug maintenance time, and maintenance therapy. Regarding botulinum toxin A, ischuria is not common after this fourth-line treatment. However, treatment should be chosen with caution in patients with obstructive voiding dysfunction. Major reconstructive surgery is rare but can be attempted when all other treatments have failed. Attempts have even been made to perform urinary diversion and cystectomy simultaneously for patients with obvious pathological findings such as Hunner lesions, severely low bladder compliance, and decreased bladder capacity. However, clinicians and patients considering this option should keep in mind that major reconstructive surgery does not guarantee the disappearance of pain. Furthermore, since continent urinary diversion surgery such as substitution cystoplasty, ileal conduit urinary diversion, Indiana pouch reservoir, and neobladder-to-urethra diversion uses a part of the small intestine, clinicians and patients should be aware when considering surgery that pain originating from the intestine and caused by the contraction of the substituted intestine cannot be excluded.

FINAL OPINIONS

We have read the article by Hanno about the definition of terms and new suggestions. At that time, we thought that the definition of terms and opinions were ambiguous for specifying or defining actual clinical situations. Now, more than ever, we believe that these implications and ambiguities should be viewed as characteristics of a condition that is defined as a combination of distinctive symptoms. Moreover, in the absence of reliable, high-quality clinical studies due to the clinical heterogeneity of IC/BPS, a reasonable animal model that represents the complexity of the disease should be established in basic research. In that case, advances should be made in standardized research, which is essential as part of clinical research that can characterize the phenotypes of various clinical situations and in reproducible and valid laboratory-based translational research. The most important development covered in this review is the epidemiological, pathological, and (more notably) distinct identifiability of the prognostic value of various treatments for Hunner lesions.

In all clinical fields, diagnoses and treatments specific to each symptom are performed, and this approach is known to be reasonable. However, patients and clinicians should be aware that this approach is very time-consuming and it is an arduous process to listen to the patients’ expressions of symptoms, to educate patients on the perception of the disease, and to form a relationship with patients for treatment. Only through these simple but laborious humane efforts can medical staff improve patients’ quality of life with the abovementioned treatments or in more effective ways. We hope that medical staff have confidence and welcome patients.

AUTHOR CONTRIBUTION STATEMENT

Conceptualization: KHK
Data curation: SJK
Formal analysis: SJK
Writing - original draft: KHK
Writing - review & editing: SJK, KHK

ORCID

Su Jin Kim 0000-0002-1917-2780
Khae Hawn Kim 0000-0002-7045-8004

REFERENCES

1. Aguiar LM, Franco I. Bladder bowel dysfunction. Urol Clin North Am 2018;45:633-40.
2. Akiyama Y, Homma Y, Maeda D. Pathology and terminology of interstitial cystitis/bladder pain syndrome: a review. Histol Histopathol 2019;34:25-32.
3. Costantini E, Illiano E, Giannitsas K, Prestipino M, Pastore AL, Carbone A, et al. Urological dysfunction in young women: an inheritance of childhood? BJU Int 2018;121:453-7.
4. Abramov Y, Goldberg RP, McGuire M, Golden B, Gandhi S, Sand PK. Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide. Urology 2004;63:1182-3.
5. Abrams P, Andersson KE, Apostolidis A, Birder L, Bliss D, Brubaker L, et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol Urodyn 2018;37:2271-2.
6. Abélha-Aleixo J, Moura M, Bernardo A, Almeida J, Brito I. Lupus cystitis and repercussions of delayed diagnosis. Acta Reumatol Port 2015;40:294-8.
7. Akiyama Y, Maeda D, Morikawa T, Niimi A, Nomiya A, Yamada Y, et al. Digital quantitative analysis of mast cell infiltration in interstitial cystitis. Neurourol Urodyn 2018;37:650-7.
8. Allen-Brady K, Rowe K, Cessna M, Lenherr S, Norton P. Significant linkage evidence for interstitial cystitis/painful bladder syndrome on chromosome 3. J Urol 2018;199:172-7.
9. Clemens JQ, Stephens-Shields A, Naliboff BD, Lai HH, Rodriguez L, Krieger JN, et al. Correlates of health care seeking activities in patients with urological chronic pelvic pain syndromes: findings from the MAPP cohort. J Urol 2018;200:136-40.
10. Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokoven A, Ellingson BM, et al. Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network. Nat Rev Urol 2019;16:187-200.
11. Cox A, Golda N, Nadeau G, Curtis Nickel J, Carr L, Corcos J, et al. CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J 2016;10:E136-55.
12. Crescenze IM, Tucky B, Li J, Moore C, Shoskes DA. Bladder dysfunction—side effects, and monitoring of oral cyclosporine in interstitial cystitis-bladder pain syndrome. Urology 2017;107:49-54.
13. Doiron RC, Kogan BA, Tolls V, Irvine-Bird K, Nickel JC. Childhood bladder and bowel dysfunction predicts irritable bowel syndrome phenotype in adult interstitial cystitis/bladder pain syndrome patients. Can Urol Assoc J 2017;11:225-9.
14. Gardella B, Porru D, Nappi D, Daccò MD, Chiesa A, Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dys-function—a case-control study. J Sex Med 2011;8:1726-34.
15. Grigorescu B, Powers K, Lazarou G. Update on urinary tract markers in interstitial cystitis/bladder pain syndrome. Female Pelvic Med Reconstr Surg 2016;22:16-23.
16. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, et al. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. Neurourol Urodyn 2018;37:1441-7.
17. Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, et al. Cogni-tive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord 2018;241:1-7.
18. Peters KM. Use of transcutaneous electrical nerve stimulation in the management of bladder pain syndrome: 2017 update. In: Hanno P, Nordling J, Staskin D, Wein A, Wyndaele J, editors. Bladder pain syndrome—an evolution. Cham: Springer International Publishing; 2018. p. 131-3.
19. Friedlander JJ, Shorter B, Moldwin RM. Diet and its role in inter-stitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int 2012;109:1584-91.
20. Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol Urodyn 2017;36:2028-33.
21. Funaro MG, King AN, Stern [NH, Moldwin RM, Bahlani S. Endo-scopic injection of low dose triamcinolone: a simple, minimally invasive, and effective therapy for interstitial cystitis with Hunner lesions. Urology 2018;118:25-9.
22. Halder GE, Scott L, Wyman A, Mora N, Miladinovic B, Bassaly R, et al. Botox combined with myofascial release physical therapy as a treatment for myofascial pelvic pain. Investig Clin Urol 2017;58:134-9.
23. Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic ef-fect: lidocaine in the diagnosis and treatment of interstitial cystitis/ bladder pain syndrome. Urology 2015;85:1025-33.
24. Hoke TP, Goldstein H, Saks EK, Vakili B. Hydrodistention of the bladder for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC). Neurourol Urodyn 2017;36:784-6.
25. Kirk PS, Santiago-Lastra Y, Qin Y, Stoffel JT, Clemens JQ, Cameron AP. The effects of cystoscopy and hydrodistention on symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol Urodyn 2018;37:2002-7.
26. Gamper M, Regauer S, Welter J, Eberhard J, Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol 2015;193:1994-2000.
27. Ichihara K, Aizawa N, Akiyama Y, Kamei J, Masumori N, Anders-son KE, et al. Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. Pain 2017;158:138-45.
28. Kim A, Han JY, Ryu CM, Yu HY, Lee S, Kim Y, et al. Histopatho-logical characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology 2017;71:415-24.
29. Maeda D, Akiyama Y, Morikawa T, Kunita A, Ota Y, Katoh H, et al. Hunner-type (classic) interstitial cystitis: a distinct inflammatory
disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS One 2015;10:e0143316.
30. Krieger JN, Stephens AJ, Landis JR, Clemens QJ, Kreder K, Lai HH, et al. Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study. J Urol 2015;193:1254-62.
31. Lai HH, Krieger JN, Pontari MA, Buchwald D, Hou X, Landis JR, et al. Painful bladder filling and painful urgency are distinct characteristics in men and women with urological chronic pelvic pain syndromes: a MAPP research network study. J Urol 2015;194:1634-41.
32. Landis JR, Williams DA, Lucia MS, Clauw DJ, Naliboff BD, Robinson NA, et al. The MAPP research network: design, patient characterization and operations. BMC Urol 2014;14:58.
33. Shim SR, Cho YJ, Shin IS, Kim JH. Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2016;48:1215-27.
34. Sutcliffe S, Colditz GA, Goodman MS, Pakpahan R, Vetter J, Ness TJ, et al. Urological chronic pelvic pain syndrome symptom flares: characterisation of the full range of flares at two sites in the multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network. BJU Int 2014;114:916-25.
35. Sutcliffe S, Jemielita T, Lai HH, Andriole GL, Bradley CS, Clemens QJ, et al. A case-crossover study of urological chronic pelvic pain syndrome flare triggers in the MAPP research network. J Urol 2018;199:1245-51.
36. Jhang JF, Hsu YH, Kuo HC. Possible pathophysiology of ketamine-induced cystitis/bladder pain syndrome-The role of bladder outlet dysfunction in the pathophysiology. Neurourol Urodyn 2018;37:1971-7.
37. Kuo TL, Ng LG, Chapple CR. Pelvic floor spasm as a cause of voiding dysfunction. Curr Opin Urol 2015;25:311-6.
38. Nickal JC, Moldwin R. FDA BRUDAC 2018 Criteria for interstitial cystitis/bladder pain syndrome clinical trials: future direction for research. J Urol 2018;200:39-42.
39. Walker SJ, Zambon J, Andersson KE, Langefeld CD, Matthews CA, Badlani G, et al. Bladder capacity is a biomarker for a bladder centric versus systemic manifestation in interstitial cystitis/bladder pain syndrome. J Urol 2017;198:369-75.
40. Patnaik SS, Laganà AS, Vitale SG, Buttìcè S, Noventa M, Gizzo S, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet 2017;295:1341-59.
41. Chai TC, Zhang CO, Shenfeld JL, Johnson HW Jr, Warren JW, Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol 2000;163:1440-4.
42. Regauer S, Gamper M, Fehr MK, Vierreck V. Sensory hyperinnervation distinguishes bladder pain syndrome/interstitial cystitis from overactive bladder syndrome. J Urol 2017;197:159-66.
43. Theoharides TC, Stewart JM. Anti-allergic compounds in chronic pelvic pain. In: Moldwin R, editor. Urological and gynaecological chronic pelvic pain. 9th ed. Cham: Springer International Publishing; 2017. p. 153-63.
44. Vera PL, Preston DM, Moldwin RM, Erickson DR, Mowlazadeh B, Ma F, et al. Elevated urine levels of macrophage migration inhibitory factor in inflammatory bladder conditions: a potential biomarker for a subgroup of interstitial cystitis/bladder pain syndrome pa-
patients. Urology 2018;116:55-62.
54. Muere A, Tripp DA, Nickel JC, Kelly KL, Mayer R, Pontari M, et al. Depression and coping behaviors are key factors in understanding pain in interstitial cystitis/bladder pain syndrome. Pain Manag Nurs 2018;19:497-505.
55. Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E. A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboB-TXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J 2014;25:593-9.
56. Morrisey D, El-Khawand D, Ginzburg N, Wehbe S, O’Hare P 3rd, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg 2015;21:277-82.
57. Olson LE, Dyer JE, Haq A, Ockrim J, Greenwell TJ. A systematic review of the literature on cystodistension in bladder pain syndrome. Int Urogynecol J 2018;29:251-7.
58. Rahnama’i MS, Marcelissen T, Apostolidis A, Veit-Rubin N, Schurch B, Cardozo L, et al. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. Neurourol Urodyn 2018;37(S4):S99-107.
59. Redmond EJ, Flood HD. The role of reconstructive surgery in patients with end-stage interstitial cystitis/bladder pain syndrome: is cystectomy necessary? Int Urogynecol J 2017;28:1551-6.
60. Chai TC, Zhang C, Warren JW, Keay S. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis. Urology 2000;55:643-6.
61. Moldwin RM. The use of pentosan polysulfate in the management of interstitial cystitis. In: Hanno P, Nordling J, Staskin D, Wein A, Wyndaele Jm editors. Bladder pain syndrome – an evolution. Cham: Springer International Publishing; 2018. p. 115-9.
62. Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology 2018;125:1793-802.
63. Rubin RS, Malphrus E. Interstitial cystitis and sexual dysfunction: diagnostic accuracy is essential. Curr Sex Health Rep 2018;10:104-8.
64. Santos JD, Lopes RI, Koyle MA. Bladder and bowel dysfunction in children: an update on the diagnosis and treatment of a common, but underdiagnosed pediatric problem. Can Urol Assoc J 2017;11 (1-2Suppl1):S64-72.
65. Han E, Nguyen L, Sirls L, Peters K. Current best practice management of interstitial cystitis/bladder pain syndrome. Ther Adv Urol 2018;10:197-211.